Validating AI Systems in GxP Environments

The pharmaceutical industry’s adoption of artificial intelligence has progressed to the point where AI systems are no longer confined to research environments and exploratory analytics. AI is entering GxP-regulated processes: manufacturing quality decisions, clinical data analysis, pharmacovigilance case processing, laboratory data interpretation, and regulatory submission preparation. This migration into regulated territory creates an urgent need for validation frameworks that can accommodate the unique characteristics of AI systems while satisfying the compliance expectations of regulatory authorities around the world.

Traditional computer system validation (CSV) methodologies, developed for deterministic software systems that produce the same output for the same input every time, are not well suited to AI systems that learn from data, may produce probabilistic outputs, and can change their behavior as they encounter new information. The pharmaceutical quality and IT community has recognized this gap, and new guidance, most notably from ISPE’s GAMP initiative and from the FDA’s evolving framework for AI credibility, is emerging to address it. However, the practical challenge of translating this guidance into operational validation practices remains significant for most organizations.

This article provides a comprehensive framework for validating AI systems in GxP environments, drawing on the latest regulatory guidance, industry standards, and practical experience from organizations that have successfully deployed validated AI in pharmaceutical operations. It is designed for quality leaders, IT directors, validation managers, and data science teams who must collaborate to bring AI into regulated processes responsibly and effectively.

The AI Validation Challenge in Regulated Pharma

The fundamental challenge of AI validation in GxP environments stems from the characteristics that make AI systems different from traditional software. Understanding these differences is essential for designing validation approaches that are rigorous without being impractical.

Non-Deterministic Behavior

Traditional software validation relies on the principle that verified inputs produce expected outputs. A validated ERP system processes a batch record the same way every time. AI systems, particularly those based on machine learning, produce outputs that are probabilistic rather than deterministic. A classification model may assign a 94 percent probability to one category and a 6 percent probability to another. The output may vary as the model encounters data that differs from its training distribution. Validation must address how the organization defines acceptable performance ranges rather than exact expected outputs.

Learning and Adaptation

Many AI systems are designed to improve over time as they process more data. This learning capability, while valuable, creates a validation challenge: the system validated today may behave differently tomorrow. Traditional CSV assumes that the validated state is static between change control events. AI validation must account for continuous or periodic model updates while maintaining the assurance that the system operates within validated performance boundaries.

Data Dependency

The performance of an AI system is inseparable from the quality and characteristics of its training data. Validating the model without validating the data is meaningless. If the training data is biased, incomplete, or unrepresentative of the population the model will encounter in production, the model’s performance will degrade regardless of how sophisticated the algorithm is. Data validation must be elevated from a supporting activity to a core component of the validation lifecycle.

Opacity and Explainability

Some AI architectures, particularly deep neural networks, function as effective black boxes where the relationship between inputs and outputs cannot be easily explained in human-interpretable terms. In GxP environments where regulators expect organizations to understand and explain their decision-making processes, this opacity creates tension. Validation approaches must address explainability requirements and establish appropriate levels of transparency based on the criticality of the AI system’s output.

Regulatory Landscape: FDA, EMA, and Global Expectations

The regulatory framework for AI in pharmaceutical operations is evolving rapidly across multiple jurisdictions. While no single regulation provides comprehensive, prescriptive requirements for AI validation in GxP contexts, a coherent set of expectations is emerging from the collective guidance of major regulatory authorities.

FDA Framework

The FDA has taken the most active role in articulating expectations for AI in pharmaceutical contexts. The agency’s proposed framework for advancing the credibility of AI models used in drug and biological product submissions, published in 2025, establishes a structured approach to demonstrating that AI-generated evidence is fit for regulatory decision-making. Key elements include context of use definition (specifying exactly how the AI model’s output will be used in the regulatory context), model risk assessment, validation evidence requirements scaled to the risk level, and ongoing performance monitoring expectations.

The FDA has also published guidance on the use of AI/ML in software as a medical device (SaMD), which, while not directly applicable to pharmaceutical manufacturing and quality systems, establishes principles for the total product lifecycle approach to AI that influence thinking about GxP AI validation. The agency’s acceptance of over 300 AI/ML-enabled submissions through 2025 demonstrates practical willingness to engage with AI-generated evidence when appropriately validated.

EMA and EU Regulatory Framework

The European Medicines Agency has adopted a more cautious posture, emphasizing the importance of transparency, reproducibility, and human oversight in AI-enabled pharmaceutical processes. The EU AI Act, while primarily targeting AI systems that interact directly with citizens, establishes risk classification and governance requirements that influence how pharmaceutical companies operating in Europe approach AI validation. AI systems used in medical device contexts are classified as high-risk under the EU AI Act, triggering mandatory conformity assessment, documentation, and human oversight requirements.

ICH and Global Harmonization

The International Council for Harmonisation (ICH) has begun integrating AI considerations into its pharmaceutical quality guidelines. While no ICH guideline is specifically dedicated to AI validation, revisions to guidelines including ICH Q8 (Pharmaceutical Development), Q9 (Quality Risk Management), and Q10 (Pharmaceutical Quality System) increasingly accommodate AI-enabled approaches. The ICH Q2(R2) guideline on analytical procedure validation provides a framework that can be adapted for validating AI-based analytical methods, and the emerging Q14 guideline on analytical procedure development explicitly considers multivariate and model-based analytical approaches.

GAMP 5 and the New GAMP AI Guide

ISPE’s GAMP (Good Automated Manufacturing Practice) framework has long been the pharmaceutical industry’s primary practical reference for computer system validation. The GAMP 5 Second Edition, released in 2022, updated the framework to emphasize critical thinking, risk-based approaches, and the importance of focusing validation effort on patient safety and product quality rather than on exhaustive testing of every system function.

The new GAMP guide specifically addressing AI, released in 2025, extends the GAMP framework to address the unique validation challenges of AI and machine learning systems. This guide represents the most comprehensive industry consensus on how to validate AI in GxP pharmaceutical environments and is essential reading for any organization deploying AI in regulated processes.

Key Principles from the GAMP AI Guide

• Risk-based approach: The level and rigor of validation activities should be proportional to the risk that the AI system poses to patient safety, product quality, and data integrity. Low-risk AI applications (such as those providing informational outputs that are reviewed by qualified humans before any regulated decision) require less extensive validation than high-risk applications (such as those that directly control manufacturing processes or generate GxP records).
• Intended use specification: The validation strategy begins with a precise definition of the AI system’s intended use within the GxP process. This specification defines what the system is expected to do, what inputs it receives, what outputs it produces, who uses those outputs, and what decisions or actions are taken based on the outputs. The intended use specification is the foundation for all subsequent validation activities.
• Data lifecycle management: The GAMP AI guide elevates data management to a first-class validation concern. Organizations must demonstrate that training data is representative, that data quality is controlled, that data provenance is documented, and that data used for ongoing model evaluation is independent of training data.
• Performance qualification: Rather than traditional operational qualification (OQ) testing that verifies system functions against specifications, AI validation emphasizes performance qualification that demonstrates the model performs acceptably across a representative range of real-world conditions. Performance must be measured using metrics appropriate to the intended use, and acceptance criteria must be defined before testing begins.
• Ongoing verification: The guide introduces the concept of ongoing verification as a mandatory component of AI validation, requiring organizations to continuously monitor model performance in production and trigger revalidation when performance degrades below defined thresholds.

Risk-Based Classification of AI Systems

The cornerstone of any practical AI validation framework is a risk classification system that determines the appropriate level of validation rigor for each AI application. The classification must consider both the inherent risk of the AI technology and the consequences of the AI system’s output within the specific GxP process where it operates.

The following classification framework integrates concepts from GAMP 5, the FDA’s risk-based approach, and the EU AI Act to provide a comprehensive basis for validation planning:

The classification should be determined through a documented risk assessment conducted by a cross-functional team including quality, IT, the business process owner, data science, and regulatory affairs. The risk assessment should consider the probability of the AI system producing an incorrect output, the severity of consequences if an incorrect output is acted upon, and the detectability of incorrect outputs through downstream controls.

The AI Validation Lifecycle: Beyond Traditional CSV

Traditional CSV follows a V-model lifecycle: user requirements, functional specifications, design specifications, coding, and then corresponding levels of testing (unit testing, integration testing, operational qualification, performance qualification). This model assumes a linear development process that produces a stable, static system. AI development is fundamentally different: it is iterative, data-driven, and produces systems that may continue to evolve after deployment.

The AI validation lifecycle must accommodate these differences while maintaining the rigor and documentation that regulators expect. The following lifecycle model adapts the V-model principles for AI systems:

Stage 1: Problem Definition and Risk Assessment

Define the business problem the AI system will address, specify the intended use within the GxP process, conduct the risk classification assessment, and establish the validation strategy. This stage produces the validation plan that governs all subsequent activities. The validation plan should define acceptance criteria for model performance, specify the data requirements for training and validation, identify the regulatory requirements that apply, and establish the governance structure for the validation effort.

Stage 2: Data Assessment and Preparation

Evaluate the quality, representativeness, and governance of the data that will be used for model training and validation. This includes assessing data completeness, accuracy, and consistency; documenting data sources and provenance; identifying and addressing potential biases; establishing data partitioning strategies (training, validation, and test sets); and implementing data quality controls that will apply throughout the model lifecycle. For GxP applications, the data assessment must also verify compliance with data integrity requirements including the ALCOA+ principles.

Stage 3: Model Development and Selection

Develop and evaluate candidate models using the training data, selecting the model that best meets the performance requirements established in Stage 1. This stage should be documented sufficiently to demonstrate that the model selection was systematic and justified. Key documentation includes the algorithms evaluated, hyperparameter optimization approaches, cross-validation results, and the rationale for selecting the final model. The development environment and tools used should be documented to support reproducibility.

Stage 4: Performance Qualification

Test the selected model against the held-out test dataset and, where possible, against real-world data that was not used during development. Performance qualification must evaluate the model against the acceptance criteria defined in Stage 1 using metrics appropriate to the intended use. For classification models, this typically includes accuracy, precision, recall, F1 score, and area under the ROC curve. For regression models, it includes mean absolute error, root mean squared error, and calibration metrics. The performance qualification must also assess model behavior on edge cases, out-of-distribution inputs, and adversarial examples appropriate to the risk category.

Stage 5: Deployment and Release

Deploy the validated model into the production environment with appropriate controls. Deployment activities include verifying that the production environment matches the validated configuration, implementing access controls and audit logging consistent with 21 CFR Part 11 and Annex 11 requirements, establishing monitoring dashboards and alerting, conducting user acceptance testing in the production environment, training end users on proper use and interpretation of AI outputs, and executing a formal release process with quality approval.

Stage 6: Ongoing Monitoring and Maintenance

Implement continuous performance monitoring that tracks model accuracy, data drift, prediction distribution changes, and system availability. Define thresholds that trigger investigation, revalidation, or model rollback. Establish a periodic review cadence (typically quarterly or semi-annually, depending on risk category) that formally evaluates model performance trends and determines whether the validated state remains current. Maintain change control procedures for model updates, data pipeline changes, and infrastructure modifications that could affect model behavior.

Data Integrity for AI Training and Inference

Data integrity, the assurance that data is accurate, complete, consistent, and reliable throughout its lifecycle, is a foundational requirement in GxP environments. For AI systems, data integrity must be maintained not only for the system’s production outputs but also for the training data that determines the model’s behavior and the evaluation data used to assess performance.

The ALCOA+ principles (Attributable, Legible, Contemporaneous, Original, Accurate, plus Complete, Consistent, Enduring, Available) provide the framework for AI data integrity:

Organizations must also establish controls for data pipeline integrity, ensuring that the automated processes that extract, transform, and load data for AI consumption maintain data quality throughout. Pipeline validation should verify that data transformations produce expected results, that data is not corrupted during transfer, and that the pipeline handles errors and exceptions gracefully without silently introducing data quality issues.

Continuous Model Monitoring and Revalidation

The requirement for continuous monitoring distinguishes AI validation from traditional CSV more than any other aspect. A traditional validated system remains in a validated state until a change is introduced. An AI system’s performance can degrade without any change to the system itself, simply because the real-world data it encounters in production differs from the data it was trained on.

Types of Drift to Monitor

• Data drift: Changes in the statistical distribution of input data compared to the training data. If the patient population changes, if manufacturing processes evolve, or if data capture practices shift, the AI system may encounter inputs that fall outside its training distribution, leading to degraded performance.
• Concept drift: Changes in the underlying relationship between inputs and outputs. The patterns the model learned during training may no longer apply because the real-world phenomenon the model represents has changed. In pharmaceutical contexts, this might occur due to changes in disease prevalence, regulatory requirements, or manufacturing technology.
• Performance drift: Gradual degradation in model accuracy as measured against ground truth labels. This may result from data drift, concept drift, or both, and is the most direct indicator that revalidation may be needed.

The monitoring infrastructure should track drift metrics continuously and compare them against thresholds defined during validation. When thresholds are breached, the monitoring system should trigger an investigation workflow that determines whether the drift represents a genuine performance concern requiring revalidation or a transient fluctuation within acceptable bounds.

Revalidation Triggers and Procedures

The validation plan should define specific conditions that trigger revalidation of the AI system. These triggers typically include performance metrics falling below defined thresholds for a sustained period, significant changes to input data sources or data quality, model retraining events (any update to model weights or parameters), changes to the production infrastructure that could affect model behavior, and regulatory guidance changes that alter validation expectations. Revalidation procedures should be defined in advance and scaled to the nature of the trigger. A minor model update on stable data may require focused performance testing against the original acceptance criteria. A major retraining on substantially different data may require a more comprehensive revalidation that revisits earlier lifecycle stages.

Documentation Requirements for GxP AI Systems

Documentation for GxP AI systems must satisfy both traditional quality system requirements and AI-specific documentation needs. The documentation package serves multiple purposes: it provides evidence of validation for regulatory inspections, it enables knowledge transfer between team members, it supports change control decisions, and it creates the audit trail that demonstrates the organization’s control over the AI system throughout its lifecycle.

Organizational Roles and Responsibilities

Validating AI systems in GxP environments requires collaboration across organizational functions that have not traditionally worked together on validation activities. Data science teams, quality assurance, IT, business process owners, and regulatory affairs must all contribute to the validation effort, and clear role definition is essential for avoiding gaps and conflicts.

The organizational challenge is not just defining roles but building the shared vocabulary and mutual understanding needed for effective collaboration. Data scientists typically have limited experience with GxP quality systems, and quality professionals may have limited understanding of AI/ML technology. Investing in cross-training, where data scientists learn GxP fundamentals and quality professionals learn AI basics, is one of the most effective accelerators for AI validation programs.

A Practical Validation Framework for Pharma AI

Translating regulatory guidance and industry standards into an actionable validation framework requires practical decisions about scope, effort, and documentation. The following framework provides a structured approach that organizations can adapt to their specific context.

Step 1: Establish the AI Validation Policy

Develop an organizational policy that defines the company’s approach to AI validation in GxP environments. This policy should reference applicable regulations and guidance, establish the risk classification framework, define minimum documentation requirements for each risk category, assign organizational responsibilities, and establish the governance structure for AI validation decisions. The policy should be approved by quality leadership and integrated into the pharmaceutical quality system.

Step 2: Create Standardized Templates and Procedures

Develop templates for the key validation documents (validation plan, intended use specification, data management plan, model development report, performance qualification protocol, monitoring SOP, and validation summary report) that are pre-configured for AI-specific content. Create procedural SOPs that define the validation workflow, approval gates, and decision criteria for each lifecycle stage. These templates and procedures should be designed to scale with risk category, providing comprehensive guidance for high-risk applications while allowing streamlined documentation for lower-risk use cases.

Step 3: Build the Monitoring Infrastructure

Implement the technical infrastructure for continuous model monitoring before deploying any GxP AI system. This includes automated performance metric calculation, drift detection algorithms, alerting and escalation workflows, and dashboards that provide visibility to both data science and quality teams. The monitoring infrastructure itself should be qualified as part of the supporting systems for the GxP AI application.

Step 4: Pilot the Framework

Apply the validation framework to a Category 2 (GxP-supporting with human review) AI application as a pilot. This allows the organization to test and refine its validation approach on a manageable-risk use case before tackling higher-risk applications. Capture lessons learned from the pilot validation and use them to improve the framework before scaling to additional applications.

Step 5: Scale and Mature

Extend the validation framework to additional AI applications, progressively addressing higher-risk categories as organizational experience and confidence grow. Conduct periodic reviews of the framework itself to incorporate regulatory updates, industry best practices, and lessons learned from validation experiences. Establish a community of practice that brings together validation, data science, IT, and business stakeholders to share knowledge and resolve emerging challenges.

Future Regulatory Direction and Preparation

The regulatory landscape for AI in pharmaceutical operations will continue to evolve significantly over the next several years. Several trends are visible that organizations should prepare for:

• Increasing specificity of regulatory expectations: As regulatory authorities gain experience reviewing AI-enabled submissions and inspecting AI-enabled operations, their expectations will become more specific and more consistently applied. Organizations that establish robust validation frameworks now will be better positioned to adapt as expectations crystallize.
• Greater emphasis on continuous monitoring: Regulatory authorities are increasingly signaling that they expect AI systems to be monitored throughout their lifecycle, not just validated at deployment. Organizations should invest in monitoring infrastructure as a priority, not as a future enhancement.
• Harmonization of global standards: As ICH and other international bodies develop AI-specific guidance, the currently fragmented regulatory landscape will move toward greater harmonization. Organizations operating globally should design their validation frameworks to accommodate the most rigorous current requirements while maintaining flexibility to adapt as harmonized standards emerge.
• Expectation of explainability: Regulators are increasingly uncomfortable with opaque AI systems, particularly for high-risk applications. Organizations should prioritize model architectures that support explainability, or invest in post-hoc explainability tools, especially for Category 3 and Category 4 applications.
• Pre-submission engagement: The FDA and other authorities are increasingly open to pre-submission discussions about AI validation approaches. Organizations deploying AI in novel regulatory contexts should take advantage of these engagement opportunities to align their validation strategies with regulatory expectations before committing to implementation.

Validating AI systems in GxP pharmaceutical environments is one of the defining challenges for quality and IT leadership in the current era of digital transformation. The traditional validation paradigm must evolve to accommodate systems that learn, adapt, and produce probabilistic outputs, while maintaining the rigor and auditability that regulators and patients require. The organizations that develop effective AI validation capabilities will unlock the full potential of AI in regulated pharmaceutical processes. Those that treat AI validation as an insurmountable barrier will cede competitive ground to more capable peers.

The path forward is clear: adopt a risk-based approach, invest in data integrity and continuous monitoring, build cross-functional collaboration between quality and data science teams, and develop practical frameworks that can mature alongside the technology and regulatory landscape. AI validation in GxP is not an abstract compliance problem; it is a practical organizational capability that can be built systematically and improved iteratively.

At Sakara Digital, we help pharmaceutical and life sciences organizations develop and implement AI validation frameworks that satisfy regulatory expectations while enabling innovation. From risk classification and validation strategy through monitoring infrastructure and inspection readiness, our team brings deep expertise in both GxP quality systems and AI technology. If your organization is navigating the challenges of AI validation in regulated environments, contact our team to discuss how we can accelerate your path to compliant, production-ready AI systems.